Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0393754 (HSA)
 2,996 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A comparative analysis of reproduction of 9 strains of hepatitis A viruses (HSA-15, CF-979, MI, MBB 11/5, H-141, KMW-1, GBM, IH-26, WR-61) from different regions of the world in cell cultures (PLC/PRF/5, HEL-240, FRhK-4, MK) revealed the differences in the capacity of the viruses for reproduction in these cell lines. The factors influencing HAV reproduction in cell cultures such as temperature, medium, and sera were studied. In one-cycle infection, accumulation of vRNA and formation of virus particles were analysed.
 ...
PMID:[The reproduction of the hepatitis A virus in cell cultures]. 165 8

The purpose of this study was to evaluate the clinical outcome of BSH-based intra-operative BNCT (IO-BNCT) and BSH and BPA-based non-operative BNCT (NO-BNCT). We have treated 23 glioblastoma patients with BNCT without any additional chemotherapy since 1998. The median survival time (MST) of BNCT was 19.5 months, and 2-year, 3-year and 5-year survival rates were 26.1%, 17.4% and 5.8%, respectively. This clinical result of BNCT in patients with GBM is superior to that of single treatment of conventional radiotherapy compared with historical data of conventional treatment.
 ...
PMID:Clinical results of boron neutron capture therapy (BNCT) for glioblastoma. 2168 70

The uptake of (10)boron by tumor cells plays an important role for cell damage in boron neutron capture therapy (BNCT). CD133 is frequently expressed in the membrane of glioma stem cells (GSCs), resistant to radiotherapy and chemotherapy, and represents a potential therapeutic target. To increase (10)boron uptake in GSCs, we created a polyamido amine dendrimer, conjugated CD133 monoclonal antibodies, encapsulating mercaptoundecahydrododecaborate (BSH) in void spaces, and monitored the uptake of the bioconjugate nanoparticles by GSCs in vitro and in vivo. Fluorescence microscopy showed the specific uptake of the bioconjugate nanoparticles by CD133-positive GSCs. Treatment with the biconjugate nanoparticles resulted in a significant lethal effect after neutron radiation due to efficient and CD133-independent cellular targeting and uptake in CD133-expressing GSCs. A significantly longer survival occurred in combination with the biconjugate nanoparticles and BSH compared with BSH alone in human intracranial GBM models employing CD133-positive GSCs xenografts. Our data demonstrated that this bioconjugate nanoparticle targets human CD133-positive GSCs and is a potential boron agent in BNCT.
 ...
PMID:Targeting glioma stem cells enhances anti-tumor effect of boron neutron capture therapy. 2719 Dec 69